Short communication: Simplified estimation of the long-term specificity of the BED assay to improve estimates of HIV incidence

AIDS Res Hum Retroviruses. 2010 Sep;26(9):977-9. doi: 10.1089/aid.2010.0009.

Abstract

The BED assay overestimates HIV incidence because a proportion, epsilon (epsilon), of chronically infected people test "false-recent." In the ZVITAMBO trial, 2796 postpartum women tested HIV positive at baseline and 5.1% tested "false-recent" by BED 12 months later, providing a population-based estimate of epsilon. At baseline, 7.2% (95% CI: 5.3-9.4) of positive women >30 years and 5.1% (95% CI: 3.5-7.2) of positive women with CD4 <200 cells/microl tested "recent" by BED. Thus, the proportions of BED-positive women in either of these subgroups (data that would be available in surveys measuring HIV and BED status) provided a reasonably tight upper bound fo epsilon, which can be used to provide a lower bound for HIV incidence.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adult
  • CD4 Lymphocyte Count
  • Enzyme-Linked Immunosorbent Assay*
  • Female
  • HIV / immunology*
  • HIV Antibodies / blood
  • HIV Infections / epidemiology*
  • Humans
  • Incidence

Substances

  • HIV Antibodies